Collaboration Between the Parties Sample Clauses

Collaboration Between the Parties. 1. Upon agreement by the Parties, one staff member from each jurisdiction shall be designated as the primary point of contact for any communication, problem solving, or needs of the program upon which this IGA is based.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Collaboration Between the Parties. 3.1 UNILIFE and SWIND shall each designate an individual to be responsible for the performance of this Agreement (“Responsible Person”) and the individuals shall cooperate and consult with each other on a reasonable basis and frequency in relation to the Industrialisation under this Agreement. UNILIFE and SWIND shall appoint their respective Responsible Person plus two other representatives each to a steering committee, which representatives shall jointly be referred to as the “Steering Committee”. The Steering Committee shall meet regularly throughout the course of the Agreement and, in any event, no less frequently than every six months. At such meetings which, unless otherwise agreed, are to take place in an agreed form mutually convenient to all the members of the Steering Committee (whether it be meetings in person, over the telephone or otherwise), questions relating to the subject matter of this Agreement shall be discussed to review the general implementation of this Agreement and to solve any pending issues in relation thereto. Exhibit 10.3 CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24b-2 Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. The omitted materials have been filed separately with the Securities and Exchange Commission.
Sample 1Sample 2
Collaboration Between the Parties. ‌ In order to fully comply with the purposes of this Agreement, each Party shall use their best efforts, if required, to provide, issue and send any information or documents required by the other Party or to comply with any request made by the other Party, provided that it is necessary or reasonable, it is not inconsistent with the provisions of this Agreement and does not involve the acceptance of new or different obligations from those stipulated herein.
Sample 1
Collaboration Between the Parties. 4.1 SANOFI CHIMIE and VIVUS shall each designate an individual contact person to be responsible for coordination of the performance of the Services under the Agreement (hereinafter the “Business Manager(s)”). The Business Manager shall cooperate and consult with each other through teleconferences or meetings, on a reasonable basis and frequency in relation to the Services to be carried out under this Agreement and all matters arising thereof. The Parties shall establish a joint manufacturing committee (the “Joint Manufacturing Committee”), which shall oversee the manufacturing of the API. VIVUS and SANOFI CHIMIE shall each appoint *** representatives with the required expertise and seniority enabling them to make operational decisions on behalf of VIVUS and SANOFI CHIMIE. From time to time, VIVUS and SANOFI CHIMIE each may substitute any of its representatives to the Joint Manufacturing Committee on prior written notice to the other Party. Each Party may invite a reasonable number of additional employees and/or advisors to attend part or all of the meetings of the Joint Manufacturing Committee. *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. The Joint Manufacturing Committee shall notably, but not limited to, (i) review the progress of the Services according to key milestones and Documentation; (ii) serve as the initial forum to resolve any issue between the Parties relating to this Agreement; (iii) serve as the forum to discuss and decide on any significant modification of Services. The Joint Manufacturing Committee shall meet as needed upon request of either Party, by teleconference or video conference, and according to a planning agreed upon by the Parties every Calendar Year. VIVUS shall be responsible for drafting the minutes of each JMC meeting and them to SANOFI CHIMIE for approval within *** Business Days of the date of the JMC meeting. In the event that SANOFI CHIMIE does not reply within *** Business Days of receipt of any JMC minutes, such minutes shall be deemed to be accepted by SANOFI CHIMIE.
Sample 1
Collaboration Between the Parties. The Parties undertake to collaborate closely in helping to implement the PhD training. The Parties are obligated to keep each other informed on all matters of importance for the implementation and collaborate actively to find solutions to any problems that might occur.
Sample 1
Collaboration Between the Parties. 5.1 The requirements pertaining to the collaboration between the Toll Charger and the EETS Provider during operation, including service conditions which the EETS Provider shall fulfill, are specified in Annex I (Service Conditions). Both Parties shall participate in the collaboration in a constructive and active manner.
Sample 1
Collaboration Between the Parties. The Parties agree to the following to ensure the Plan meets both Parties’ needs: • Each Party will notify the other Party of any meetings scheduled with the Consultant and will give the other Party the opportunity to attend such meeting. • Each Party shall include the other Party in all written communications with the Consultant and any sub-consultants. • The Parties shall mutually agree upon any changes to the Scope of Services attached as Exhibit A to the Consultant’s Agreement prior to CITY’s execution of the Consultant’s Agreement, or an amendment to the Consultant’s Agreement, with the Consultant. • Neither Party shall release information from the Plan to any third party without coordinating with the other Party. Both Parties agree to notify the other immediately upon any request for any records created pursuant to the Consultant’s Agreement that the Parties have not previously agreed to be released. To the extent that a Party receives a request to disclose any such records, and the Party does not identify a legal basis to withhold such records, the Party shall provide written notice to the other Party, and the other Party shall be given a reasonable opportunity to seek a court order to preclude the Party to whom the request was made from disclosing such records, or applicable portion thereof, provided that in such event the other Party shall defend, indemnify, and hold the Party to whom the request was made harmless regarding any claim or litigation by an third party, and such obligation shall survive termination of this Agreement. Except as expressly provided herein, this provision shall not impact either Party’s ability to timely respond to any legally required release of such records.
Sample 1
AutoNDA by SimpleDocs
Collaboration Between the Parties. Each Party undertakes to collaborate actively to ensure the proper execution of the Experiment. Each Party undertakes to report any difficulties about which it becomes aware as and when they arise, to enable the other Party to take the necessary measures. The Parties acknowledge that the proper execution of the Experiment depends on this necessary active collaboration.
Sample 1
Collaboration Between the Parties 
Sample 1Sample 2

Related to Collaboration Between the Parties

  • Consultation Between the Parties ALPS and the Trust shall regularly consult with each other regarding ALPS’ performance of its obligations under this Agreement. In connection therewith, the Trust shall submit to ALPS at a reasonable time in advance of filing with the SEC reasonably final copies of any amended or supplemented registration statement (including exhibits) under the 1933 Act and the 1940 Act; provided, however, that nothing contained in this Agreement shall in any way limit the Trust’s right to file at any time such amendments to any registration statement and/or supplements to any prospectus or statement of additional information, of whatever character, as the Trust may deem advisable, such right being in all respects absolute and unconditional.

  • Relationship Between the Parties A Party is not by virtue of this Agreement the employee, agent or partner of the other Party and is not authorised to bind or represent the other Party.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Collaboration Agreement The Collaboration Agreement shall not have been terminated in accordance with its terms and shall be in full force and effect.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Negotiation Between Executives The parties shall first attempt to resolve any dispute arising out of this Order by prompt negotiation between executives who have authority to settle the matter.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • AGREEMENT OF THE PARTIES The language used in this Agreement will be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto. Neither Executive nor the Company shall be entitled to any presumption in connection with any determination made hereunder in connection with any arbitration, judicial or administrative proceeding relating to or arising under this Agreement.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Time is Money Join Law Insider Premium to draft better contracts faster.